Zelandopam: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Task 3: Disable the categories on this page while it is still a draft, per WP:DRAFTNOCAT/WP:USERNOCAT |
||
Line 73: | Line 73: | ||
{{Dopamine receptor modulators}} |
{{Dopamine receptor modulators}} |
||
{{Draft categories| |
|||
[[Category:Abandoned drugs]] |
[[Category:Abandoned drugs]] |
||
[[Category:Catechols]] |
[[Category:Catechols]] |
||
Line 78: | Line 79: | ||
[[Category:Peripherally selective drugs]] |
[[Category:Peripherally selective drugs]] |
||
[[Category:Tetrahydroisoquinolines]] |
[[Category:Tetrahydroisoquinolines]] |
||
}} |
|||
Revision as of 06:00, 21 October 2024
This article, Zelandopam, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
This article, Zelandopam, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Clinical data | |
---|---|
Other names | Selandopam; (–)-(S)-7,8-Dihydroxy-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline; 7,8-DDPTI; YM-435; YM435; MYD-37; MYD37 |
Routes of administration | Intravenous administration |
Drug class | Dopamine D1-like receptor agonists |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H15NO4 |
Molar mass | 273.288 g·mol−1 |
3D model (JSmol) | |
| |
|
Zelandopam (INN ; developmental code names YM-435, MYD-37) is a selective dopamine D1-like receptor agonist related to fenoldopam which was under development in Japan for the treatment of hypertension and heart failure but was never marketed.[1][2][3] The drug was being developed for use by intravenous administration.[1] The development of zelandopam appears to have been discontinued by the early 2000s.[1] It was first described in the scientific literature by 1991.[4]
References
- ^ a b c "Zelandopam hydrochloride". AdisInsight. 22 May 2002. Retrieved 21 October 2024.
- ^ Doggrell SA (May 2002). "The therapeutic potential of dopamine modulators on the cardiovascular and renal systems". Expert Opin Investig Drugs. 11 (5): 631–644. doi:10.1517/13543784.11.5.631. PMID 11996645.
- ^ Vaz de Castro PA, Jose PA, Simões e Silva AC (August 2022). "Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure". Clin Sci (Lond). 136 (16): 1205–1227. doi:10.1042/CS20220338. PMID 35979889.
- ^ Giammattei, C. E., Handa, R. K., & Strandhoy, J. W. (1991). The DA1 agonists, YM435 (YM) and fenoldopam (F), inhibit oxygen consumption (QO2) in rat renal proximal tubules. Pharmacologist, 33, 210p. https://scholar.google.com/scholar?cluster=13521937496129958590